1. Home
  2. GSL vs COLL Comparison

GSL vs COLL Comparison

Compare GSL & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GSL

Global Ship Lease Inc New

HOLD

Current Price

$44.48

Market Cap

1.5B

ML Signal

HOLD

Logo Collegium Pharmaceutical Inc.

COLL

Collegium Pharmaceutical Inc.

HOLD

Current Price

$24.00

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GSL
COLL
Founded
2007
2002
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.2B
IPO Year
2008
2015

Fundamental Metrics

Financial Performance
Metric
GSL
COLL
Price
$44.48
$24.00
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
5
Target Price
$44.00
$51.40
AVG Volume (30 Days)
363.5K
832.2K
Earning Date
05-18-2026
05-07-2026
Dividend Yield
6.34%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$780,567,000.00
Revenue This Year
N/A
$8.01
Revenue Next Year
N/A
N/A
P/E Ratio
$3.49
N/A
Revenue Growth
N/A
23.62
52 Week Low
$27.28
$24.47
52 Week High
$45.45
$50.79

Technical Indicators

Market Signals
Indicator
GSL
COLL
Relative Strength Index (RSI) 59.19 24.40
Support Level $37.00 N/A
Resistance Level $45.07 $35.89
Average True Range (ATR) 0.98 1.18
MACD 0.05 -0.18
Stochastic Oscillator 75.63 0.36

Price Performance

Historical Comparison
GSL
COLL

About GSL Global Ship Lease Inc New

Global Ship Lease Inc is a containership owner, leasing ships to container shipping companies under industry-standard, fixed-rate time charters. Its fleet comprises mid-size Post-Panamax, Cypress, and smaller containerships, which tend to serve the faster-growing non-Mainlane and intra-regional trades, collectively representing the majority of the containerized trade volume globally. The company generates revenue from chartering its vessels to liner companies.

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.

Share on Social Networks: